Clinical Trial Update: GVM±R in Patients With Relapsed or Refractory Aggressive NHL [Phase 1]

View source ↗

Summary

A Phase 1 trial of GVM±R in relapsed or refractory aggressive non-Hodgkin lymphoma is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• GVM±R

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Non Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING